Detalhe da pesquisa
1.
The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors.
Oncologist
; 28(7): 628-632, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37141403
2.
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.
Lancet Oncol
; 22(6): 813-823, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34000245
3.
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
Acta Neuropathol
; 141(6): 945-957, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33740099
4.
Epigenetic landscape reorganization and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma.
bioRxiv
; 2024 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38562747
5.
Queries Raised During Oncology Business Pipeline Meetings at the European Medicines Agency: A 5-Year Retrospective Analysis.
Clin Pharmacol Ther
; 114(5): 1043-1049, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37539657
6.
Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033.
Neuro Oncol
; 25(8): 1443-1449, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36571817
7.
IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas.
Neuro Oncol
; 25(4): 701-709, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35972438
8.
Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.
Eur J Cancer
; 175: 214-223, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36152406
9.
Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial.
Clin Cancer Res
; 28(11): 2440-2448, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35294545
10.
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
Clin Cancer Res
; 28(12): 2527-2535, 2022 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35275197
11.
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
Neuro Oncol
; 23(9): 1547-1559, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33914057
12.
Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
Neuro Oncol
; 22(4): 515-523, 2020 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31637414
13.
Glioblastoma lacking necrosis or vascular proliferations: Different clinical presentation but similar outcome, regardless of histology or isolated TERT promoter mutation.
Neurooncol Adv
; 5(1): vdad075, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37441086
14.
MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas.
Neuro Oncol
; 24(4): 665-667, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35099533